HDHaafizah Dania

Haafizah Dania

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haafizah Dania has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medication adherence and glycemic control outcomes among type 2 diabetes mellitus patients

    by Mita Ardila, Haafizah Dania, Siswandi, Woro Harjaningsih, Dyah Aryani Perwitasari, Imaniar Noor Faridah, Adnan, Chatarina Danik Wijayanti, Lidwina Tika Trisnawati, Andri Christianalusi, et al.

    Type 2 Diabetes Mellitus (T2DM) remains a major public health concern in Indonesia due to its high prevalence and potential to cause various long-term complications when glycemic control is not adequately maintained. Medication adherence and barriers to treatment are important factors that may influence therapeutic outcomes. This study investigated medication adherence, insulin-related treatment barriers, and their association with glycemic outcomes among patients with T2DM at RSPAU dr. Suhardi Hardjolukito Hospital, Yogyakarta. Employing a cross-sectional approach, this research gathered data between September and October 2024. Criteria for eligibility included adult individuals with T2DM who were treated with oral antidiabetic agents, insulin, or both and provided informed consent. Medication-taking behavior was evaluated by utilizing the Medication Adherence Report Scale (MARS-5) framework, while barriers to insulin therapy were evaluated using a specific questionnaire. Associations between adherence status and glycemic parameters were examined through Fisher's Exact Test. A total of 73 patients participated, most of whom were receiving oral therapy (65.8%), a combination of metformin and glimepiride (19.2%), or metformin and acarbose (11.0%). Among insulin users, the majority had low barriers to insulin use (92.0%). Statistical analysis yielded p-values of 0.038 and 0.000 for the associations between medication adherence and fasting blood glucose as well as HbA1c levels, and for the relationship between adherence status and random blood glucose measurements, a p-values = 0.542 was obtained. The findings demonstrated that therapeutic compliance is significantly correlated with both HbA1c and fasting blood sugar levels among individuals suffering from type 2 diabetes mellitus at RSPAU dr. Suhardi Hardjolukito Hospital, Yogyakarta. These results highlight the contribution of adherence behavior to successful glycemic management. Therefore, healthcare professionals are advised to implement strategies that encourage medication adherence to optimize glycemic control.

  • Open Access

    New, Valid, and Reliable Indonesian Version of the Quality of Life Assessment Instrument Based On the Health Condition: Health-Related Quality of Life With Six Dimensions

    by Imaniar Noor Faridah, Dyah Aryani Perwitasari, Haafizah Dania, Mohammad Adam Bujang

    Health-related quality of life is very important to be measured as the parts of Patient-Reported Outcome (PRO). PRO can show the disease proression and also may influence the clinical decision making. There are many QoL instruments available in Indonesia as generic and specific instruments, however, there is no QoL instrument which measured the respondents’ functions based on the health status. This study is aimed to translate, adapt and validate the new QoL instrument based on the health condition, namely HRQ-6D (Health Related Quality of Life, 6 Dimensions). We conducted forward and backward translations. The subjects were people who lived in Yogyakarta city with aged more than 18 years old, and agreed to participate in this study. While the exclusion criteria were patients whose questionnaire data were incomplete. We shared the questionnaire to the area of Yogyakarta from September to October 2023. We used Pearson correlation, Cronbach alpha reliability test and Student T-test for the validity and reliability assessment. We recruited 69 respondents with mostly female (60.9%) and the age is more than 60 yo (80.9%). Based on the health condition, more than fifty percent of the subjects (59.4%) were in Category 1, which considered as healthy, and only one subject were having more than one disease and have been hospitalized more than three times due to the disease or the complications (Category 4). The reliability test showed the Cronbach alpha value between 0.60-0.75. And all of the items in the questionnaire met the convergent and discriminant validity. TheHRQ-6D can be implemented as the new Bahasa Version of QoL instrument, supported with the validity and reliability assessment.


  • Open Access

    Antiemetic prophylaxis utilization in cancer patients in a hospital in Yogyakarta Special Region

    by Imaniar Noor Faridah, Dyah Aryani Perwitasari, Siswandi, Lamhot B Simanjuntak, Gugun Suhendra, Dewi Wulandari, Haafizah Dania, Muhammad Arif Rizky, Safira Nur Islami, Salma Auliya Fatimah

    Chemotherapy is a type cancer treatment that uses anticancer drugs to inhibit cell division and kill cancer cells. Chemotherapy can cause side effect due to normal cells damages. The study aimed to investigate the use of antiemetic prophylaxis as premedication to prevent or reduce side effects on cancer patients undergoing chemotherapy. It was a observational study with retrospective design using medical records data of cancer patients who underwent chemotherapy in a hospital in Yogyakarta Special Region during May – September 2022. The results showed the cancer patients were dominated by women (85.71%) with ages 46-65 yr (63.27%) and stage III cancer (87.76%). There were 18 types of anticancer drugs and the most widely used drugs were doxorubicin 60 mg for the moderate emetogenic category and vinorelbine 37.5 mg for the low emetogenic category. The most widely used premedication regimen was a combination granisetron 3 mg, ondansetron 8 mg, and dexamethasone 10 mg regimen (72.45%). This combination was most often used for the cancer patients with the moderate emetogenic category (39 patients or 49.4%). However, not all the cancer patients undergoing chemotherapy with the low and moderate emetogenic anticancer drugs were administered the premedication. In conclusion, doxorubicin and vinorelbine are the most widely used for cancer patients undergoing chemotherapy in the hospital. In addition, a combination of granisetron, ondansetron, and dexamethasone is widely used as premedication.

  • Open Access

    Genetic polymorphism and the risk of diabetic foot: a bibliometric analysis from 2011-2021

    by Rita Maliza, Lalu Muhammad Irham, Jaka Pradika, Kharisma Pratama, Haafizah Dania, Bramadi Arya, Dyah Aryani Perwitasari

    Diabetic foot ulcer (DFU) has been associated with genetic and environmental factors, which could potentially have a role in DFU development. Single nucleotide polymorphisms (SNPs) in genes linked to DFU, including inflammation. Bibliometric studies on the SNP on genes affecting DFU still have not been evaluated. This study aims to depict bibliographically and understand the topic trend of genetic polymorphism and the risk of DFU publications. A bibliometric methodology was applied in this study. The data were extracted through the Scopus database from 2011 to 2021. VOS viewer was used to classify and summarize Scopus articles. The 35 articles were evaluated. India topped the list of countries with the most publications, and Tehran University of Medical Sciences was the primary institution. Singh K and his team were the first contributing authors with 44 citations. Keywords analysis indicated that the research hotspots were DFU, type 2 diabetes mellitus (T2DM), diabetic foot ulcers, polymorphisms, hypoxia, vascular endothelial growth factor (VEGF), diabetic foot, diabetes mellitus, and oxidative stress. This study summarizes the current state, trends in genetic polymorphism and risk with DFU research. It may provide researchers with insight into the genetic polymorphism and risk associated with DFU research, as well as useful information for identifying possible collaborators and partner institutions.


  • Open Access

    Genetic Association Studies of MICB and PLCE1 with Severity of Dengue in Indonesian and Taiwanese Populations

    by Imaniar Noor Faridah, Haafizah Dania, Rita Maliza, Wan-Hsuan Chou, Wen-Hung Wang, Yen-Hsu Chen, Dyah Aryani Perwitasari, Wei-Chiao Chang

    Dengue is an arboviral disease that has spread globally and become a major public health concern. A small proportion of patients may progress from symptomatic dengue fever (DF) to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Findings from a previous genome-wide association study (GWAS) demonstrated that variations in the major histocompatibility complex (MHC) class I chain-related B (MICB) and the phospholipase C epsilon 1 (PLCE1) genes were related to DSS in a Vietnamese population. This study investigated associations of variations in MICB (rs3132468) and PLCE1 (rs3740360, rs3765524) with dengue severity and thrombocytopenia in both the Indonesian and Taiwanese populations. We sampled 160 patients from the Indonesian population and 273 patients from the Taiwanese population. None of the patients had DSS in the Taiwanese population. Based on age demographics, we found that dengue is more prevalent among younger individuals in the Indonesian population, whereas it has a greater impact on adults in the Taiwanese population. Our results showed the association between MICB rs3132468 and DSS. In addition, an association was identified between PLCE1 rs3740360 and DHF in secondary dengue in Indonesian patients. However, there is no association of MICB or PLCE1 variants with thrombocytopenia. This study highlights the value of genetic testing, which might be included in the clinical pathway for specific patients who can be protected from severe dengue.


  • Open Access

    Quality of Life of Cancer Patients during Chemotherapy in Indonesia: A Comparison of EORTC QLQ-C30 and EQ-5D-5L, Based on Patients’ Characteristics

    by Dyah A. Perwitasari, Fredrick D. Purba, Susan F. Candradewi, Haafizah Dania, Lalu Muhammad Irham, Imaniar Noor Faridah, Bayu P. Septiantoro

    One of the important outcomes to define the success of cancer treatment is the health-related quality of life (HRQoL) that can be measured using generic and/or specific instruments. Our study aims to define the cancer patients’ HRQoL in some hospitals in Indonesia as measured by the European Organization for Research and Treatment for Cancer (EORTC QLQ-C30) and the EQ-5D-5L, to define the differences of cancer patients’ HRQoL referring to patients’ characteristics, and to explore determinants of cancer patients’ HRQoL. We recruited 451 cancer patients using a cross-sectional design in two referral hospitals in Central Java, Indonesia, using the purposive sampling technique. All subjects, recruited from July 2020 to October 2021, met the inclusion criteria, namely, adult patients diagnosed with cancers in all stages who willingly participated in the study. The Indonesian value set was used to obtain the EQ-5D-5L index score. We further analyzed the data based on cancer stages and compared two questionnaires using independent t test. We highlighted that most of the cancer patients are female (69.4%), young (86%), and at advanced stages of cancer (54.1%). The physical and role functions and global health status of the cancer patients are poor, and the most severe symptom is fatigue. Moreover, most of them experience severe pain and perform daily activities with difficulties. Some patients’ characteristics show significant influences on the HRQoL domains in both questionnaires ( ). Interestingly, both of the questionnaires have shown significant correlations between similar domains and revealed the poor HRQoL of advanced cancer patients ( ). Our study finds that cancer patients still have poor HRQoL in some domains. We suggest to the health providers that they apply education and psychological intervention to increase their HRQoL.


  • Open Access

    Tingkat Kepatuhan Penggunaan Obat Anti Tuberkulosis Paru di Rumah Sakit PKU Muhammadiyah Bantul Menggunakan Metode Pill-Count dan MARS

    by Miftahul Afwansyah, Haafizah Dania

    Penyakit tuberkulosis menjadi salah satu kasus kematian tertinggi sehingga perlu perhatian khusus dalam upaya pencegahan dan penanggulangannya agar menghentikan penularan. Kepatuhan meminum obat merupakan faktor penting dalam keberhasilan pengobatan tuberculosis (TB), sehingga mengurangi resiko gagal pengobatan atau kuman mycobacterium resisten terhadap obat (Multi Drug Resistant Tuberculosis). Penelitian ini bertujuan untuk mengetahui gambaran tingkat kepatuhan pengobatan pasien TB di RS PKU Muhammadiyah Bantul. Penelitian ini menggunakan desain observasional deskriptif dengan studi cross-sectional. Metode yang dilakukan yaitu wawancara menggunakan kuesioner Medication Adherence Rating Scale (MARS) dan Pill-count, dengan kriteria inklusi yaitu Pasien TB Paru diagnosis ICD-10 kode A15.0, berusia >17 tahun, telah menjalani terapi OAT-kategori I minimal selama 1 bulan. Pasien dikatakan patuh berdasarkan metode pill count yaitu, sedangkan kepatuhan dengan metode MARS dibagi mejadi 3 kategori yaitu kategori tinggi jika skor 25, kategori sedang jika skor 6-24, kategori rendah jika skor ≤5. Hasil penelitian dari 30 subyek penelitian diketahui hasil pengukuran kepatuhan menggunakan metode Pill-Count diketahui 100% pasien patuh dan hasil pengukuran tingkat kepatuhan menggunakan metode MARS diketahui 77% pasien memiliki tingkat kepatuhan tinggi, 23% pasien memiliki tingkat kepatuhan sedang. Hasil penelitian dapat disimpulkan bahwa pasien tuberkulosis di RS PKU Muhammadiyah Bantul patuh, dengan tingkat kepatuhan tinggi dan sedang.


  • Open Access

    Identification of gene expression location of angiotensin‐converting enzyme‐2 SNPs as a receptor for SARS‐CoV‐2 in different populations by using various databases

    by Dyah Aryani Perwitasari, Rita Maliza, Bayu Tri Murti, Haafizah Dania, Athika Darumas Putri

    The World Health Organization (WHO) has announced that Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) and Coronavirus disease (COVID‐19) is considered a worldwide pandemic. Rapidly rising numbers of patients have been reported in almost every country, along with the growing mortality rates. Uncontrolled growth in patient numbers may be due to reasons such as treatment options and vaccine availabilities and unidentified targets of SARS‐CoV‐2. Previous study has revealed that the molecular target of SARS‐CoV‐2 is analogous to SARS (2003), i.e. angiotensin‐converting enzyme‐2 (ACE‐2). Therefore, the determination of ACE‐2 may enrich existing information and facilitate development of drugs targeted toward SARS‐CoV‐2. This study aims to screen the expression of ACE‐2 genes and their relationship to the types of SNP variants in SARS‐CoV‐2. We explored a series of observations using powerful databases, e.g. GTEx portal, HaploReg, 1000 Genome and Ensembl, to identify the gene variant of ACE‐2. We showed that ACE‐2 is highly expressed in the testes and small intestine, while its lowest level is observed in lymphocytes. Subsequently, we observed 17 gene variants containing a missense mutation potentially damaging protein level. Among these genes, single nucleotide polymorphism (SNP) rs370187012 shows the highest damage‐level score, while the lowest effect is in SNP rs4646116. The highest frequency of the C allele was observed in European populations (1%). In addition to showing that ACE‐2 is expressed in several organs, we concluded that the ACE‐2 gene variation can be found in African, American, Southeast and East Asian, and European populations. The polymorphisms of ACE‐2 impact on the ACE2 protein structure and the binding capacity of the ACE‐2 receptor with the S‐Protein of SARS‐CoV‐2.

  • Open Access

    Variation of CYP2C9 Gene and Glycemic Control in Diabetic Patients: A Literature Review

    by Nidaul Makwa, Dyah A Perwitasari, Imaniar N Faridah, Lalu M Irham, Haafizah Dania, Rita Maliza